6533b852fe1ef96bd12ab70c

RESEARCH PRODUCT

Intravitreal pegaptanib sodium for refractory pseudophakic macular oedema.

Salvador Garcia-delpechE. CerveraManuel Díaz-llopisPatricia Udaondo

subject

Pars planaMalemedicine.medical_specialtyVisual acuityTriamcinolone acetonidegenetic structuresPseudophakiamedicine.medical_treatmentPegaptanibIntraocular lensVitrectomyAngiogenesis InhibitorsMacular EdemaVitrectomymedicinePegaptanib SodiumHumansProspective StudiesFluorescein AngiographyAgedDiabetic Retinopathymedicine.diagnostic_testbusiness.industryAptamers NucleotideMiddle AgedFluorescein angiographyeye diseasesSurgeryOphthalmologymedicine.anatomical_structureTreatment OutcomeFemalesense organsmedicine.symptombusinessTomography Optical Coherencemedicine.drug

description

Evaluate the efficacy of intravitreal pegaptanib sodium (Macugen®) in refractory pseudophakic cystoid macular oedema (CME). Prospective, nonrandomized, interventional case series. Four eyes of four patients with refractory pseudophakic CME to pars plana vitrectomy and intravitreal bevacizumab and triamcinolone, were treated with pegaptanib sodium, with a mean follow up of 4 months. Pre- and postinfection examinations included assessment of best-corrected visual acuity (BCVA) using the Early Treatment Diabetic Retinopathy Study chart (ETDRS), fluorescein angiography (FA), and optical coherence tomography (OCT). Visual acuity increased in all patients after intravitreal pegaptanib sodium. OCT showed improvement of the retinal thickness in the macular area. Intravitreal pegaptanib sodium (Macugen®) is a promising treatment for pseudophakic cystoid macular oedema resistant to other medical treatment strategies. However, further study is needed to assess the treatment's long term efficacy and the need for retreatment.

yearjournalcountryeditionlanguage
2008-04-18Eye (London, England)
10.1038/eye.2008.2https://pubmed.ncbi.nlm.nih.gov/18425062